IBO_OUT_1 [2025-04-04 04:02:51 -0400] 3660 Bytes | 1020 tokens | Cum: 1020 tkns (12.75% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Impact BioMedical (IBO) hit my radar screen, up to 0.90275 from a prev close of 0.464 Do you think its got more juice or is it lacking potential? It's 4:02:50 AM on Fri Apr 04, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: Impact BioMedical (IBO)
IPO: 2024-09-16 (6 Months Ago)
Market Cap: $9,433,243
Shares Outstanding: 12,090,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XASE
Description: Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.

Here’s the first list of news for Impact BioMedical:

C1 - Mar-21-25 02:38PM - Impact Biomedical Inc. Announcement Stock Activity/Pricing
C2 - Feb-26-25 08:30AM - Impact Biomedical Inc. Announces Acquisition of Celios , Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality
C3 - Feb-26-25 08:30AM 08:30AM - DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth
C4 - Jan-23-25 04:30PM - Impact BioMedical Inc. to Present at The Microcap Conference
C5 - Nov-19-24 08:00AM - Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision
C6 - Nov-18-24 07:00AM - Impact BioMedical Inc. (NYSEAmerican: IBO): Targeting Chronic Diseases with Patented Breakthroughs
C7 - Nov-11-24 07:30AM - Positioned for Growth: Impact BioMedical Inc.'s (NYSEAmerican: IBO) Push into Cancer and Immune Health
C8 - Oct-15-24 06:00AM - Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker Technology Targeting Inflammatory Disease

Prior AI Reports for IBO:
1. 2025-04-03 – Score: 30 – Target: 0.8700 – Highs: 0.5500 / – / –
financial-turmoil-looms-as-companys-sales-and-performance-plummet
2. 2025-04-01 – Score: 30 – Target: 1.3000 – Highs: 1.3600 / 0.6200 / 0.55
company-struggles-amidst-poor-performance-and-high-insider-ownership
3. 2025-03-21 – Score: 92 – Target: 6.2000 – Highs: 6.1700 / 4.5000 / 4.10
impact-biomedical-soars-despite-sales-drop-targets-50-price-increase
4. 2025-03-20 – Score: 70 – Target: 2.5000 – Highs: 2.4800 / 6.1700 / 4.50
impact-biomedical-shows-mixed-performance-amid-high-investor-interest

(Note: Highs = Same day / 2nd day / 3rd day)

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: Impact BioMedical (IBO).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

IBO_OUT_3 [2025-04-04 04:02:54 -0400] 1098 Bytes | 300 tokens | Cum: 1323 tkns (16.54% of 8k)
==========================================================================

Showing C1 (chunk 1 of 2): C1:
**Impact Biomedical Inc. Announcement Stock Activity/Pricing**
Date: Mar-21-25 02:38PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/21/3047292/0/en/Impact-Biomedical-Inc-Announcement-Stock-Activity-Pricing.html

March 21, 2025 14:38 ET| Source:IMPACT BIOMEDICAL INCIMPACT BIOMEDICAL INC

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price.

Impact BioMedical Inc. (NYSE American: IBO) discovers, confirms, and patents unique science and technologies which can be developed into new offe

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IBO_OUT_5 [2025-04-04 04:02:55 -0400] 976 Bytes | 300 tokens | Cum: 1685 tkns (21.06% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-03T21:05:48Z - 12 Health Care Stocks Moving In Thursday's After-Market Session - Aldeyra Therapeutics (NASDAQ:ALDX)...
A2 - 2025-04-03T17:06:22Z - 11 Health Care Stocks Moving In Thursday's Intraday Session - Aldeyra Therapeutics (NASDAQ:ALDX), Ap...
A3 - 2025-04-03T01:06:05Z - Impact Biomedical's Chan Heng Fai Ambrose sells $2.9m in stock By Investing.com...
A4 - 2025-04-03T01:06:06Z - Impact Biomedical's Chan Heng Fai Ambrose sells $2.9m in stock By Investing.com...
A5 - 2025-04-03T01:06:06Z - Impact Biomedical's Chan Heng Fai Ambrose sells $2.9m in stock By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

IBO_OUT_7 [2025-04-04 04:03:01 -0400] 1098 Bytes | 335 tokens | Cum: 2022 tkns (25.27% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Thursday's After-Market Session - Aldeyra Therapeutics (NASDAQ:ALDX), Aditxt (NASDAQ:ADTX)**Date: 2025-04-03Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44637576/12-health-care-stocks-moving-in-thursdays-after-market-sessionGainers Impact BioMedical IBO shares increased by 94.6% to $0.9 during Thursday's after-market session. The company's market cap stands at $10.3 million. Entero Therapeutics ENTO shares moved upwards by 85.35% to $0.81. The market value of their outstanding shares is at $3.8 million. Sangamo Therapeutics SGMO shares rose 29.54% to $0.81. The market value of their outstanding shares is at $180.9 million. Aldeyra Therapeutics ALDX shares rose 15.19% to $1.63. The market value of their outstanding shares is at $97.0 million. Ernexa Therapeutics ERNA shares

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IBO_OUT_9 [2025-04-04 04:03:02 -0400] 1055 Bytes | 314 tokens | Cum: 2470 tkns (30.88% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-21T18:38:00Z - Impact Biomedical Inc. Announcement Stock Activity/Pricing
B2 - 2025-02-26T13:30:00Z - Impact Biomedical Inc. Announces Acquisition of Celios®, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality"
B3 - 2024-12-12T20:56:00Z - Contractor Wins Prestigious Award for Exquisite Ornamental Staircase
B4 - 2024-10-25T11:00:00Z - ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at EMUC 2024
B5 - 2024-10-15T10:00:00Z - Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease
B6 - 2024-09-17T15:29:05Z - Impact BioMedical Inc. Announces the Closing of its Initial Public Offering

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IBO_OUT_11 [2025-04-04 04:03:04 -0400] 653 Bytes | 172 tokens | Cum: 2644 tkns (33.05% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Impact Biomedical Inc. Announcement Stock Activity/Pricing**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/21/3047292/0/en/Impact-Biomedical-Inc-Announcement-Stock-Activity-Pricing.htmlImpact BioMedical Inc. announced that there has been no material development in its business affairs not previously disclosed or any other reason to account for the unusual market action regarding its share price.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IBO_OUT_13 [2025-04-04 04:03:05 -0400] 1092 Bytes | 297 tokens | Cum: 2993 tkns (37.41% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-03 8-K Item 1.01. Entry Into a Material Definitive Agrmt.

Debt Conversion Agrmt

As previously reported on the Companys current report on Form 8-K, filed March 28, 2025 (the Initial 8-K), Impact BioMedical Inc. (the Company) entered into a Debt Conversion Agrmt (the Debt ...

S2 - 2025-04-03 8-K Item 1.01. Entry Into a Material Definitive Agrmt.

Debt Conversion Agrmt

As previously reported on the Companys current report on Form 8-K, filed March 28, 2025 (the Initial 8-K), Impact BioMedical Inc. (the Company) entered into a Debt Conversion Agrmt (the Debt ...

S5 - 2025-03-28 10-K ITEM 7 - MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

FORWARD-LOOKING STATEMENTS

Certain statements contained herein this report constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act o...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IBO_OUT_15 [2025-04-04 04:03:10 -0400] 1047 Bytes | 287 tokens | Cum: 3282 tkns (41.02% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 1.01. Entry Into a Material Definitive Agreement.

Debt Conversion Agreement

As previously reported on the Companys current report on Form 8-K, filed March 28, 2025 (the Initial 8-K), Impact BioMedical Inc. (the Company) entered into a Debt Conversion Agreement (the Debt Conversion Agreement), dated March 24, 2025, with DSS, Inc. (DSS), pursuant to that certain Amended and Restated Promissory Note, dated September 16, 2024 (the Promissory Note). The original principal amount of the Promissory Note was $12,000,000, and as of March 24, 2025, the Promissory Note had a principal balance of $13,176,477.03.

In connection with the Initial 8-K, given current market conditions, DSS has withdrawn from the Debt Conversion Agreement at this time. As such, no shares have been issued in connection with the Debt Conversion Agreement....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IBO_OUT_17 [2025-04-04 04:03:21 -0400] 5444 Bytes | 1533 tokens | Cum: 4939 tkns (61.74% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+------------------------+-----------------------+-------------------------+
| Volume: 5,882,694 | Perf Month: -60.68% | Option/Short: No / No | Sales Y/Y TTM: -100.00% |
+--------------------+------------------------+-----------------------+-------------------------+
| Avg Volume: 3.81M | Perf Quarter: -68.00% | Short Float: 0.17% | ROE: -167.65% |
+--------------------+------------------------+-----------------------+-------------------------+
| Rel Volume: 1.55 | Index: - | Short Ratio: 0.00 | ROI: -580.23% |
+--------------------+------------------------+-----------------------+-------------------------+
| RSI (14): 40.33 | Market Cap: 5.34M | Short Interest: 0.01M | Sales Surprise: - |
+--------------------+------------------------+-----------------------+-------------------------+
| ATR (14): 0.71 | Shs Outstand: 11.50M | Beta: - | EPS Surprise: - |
+--------------------+------------------------+-----------------------+-------------------------+
| SMA20: -67.94% | Shs Float: 5.16M | Sales Q/Q: - | P/E: - |
+--------------------+------------------------+-----------------------+-------------------------+
| SMA50: -72.35% | Inst Own: 0.77% | Sales past 5Y: 0.00% | Earnings: - |
+--------------------+------------------------+-----------------------+-------------------------+
| SMA200: -75.78% | Insider Own: 55.15% | Employees: 2 | |
+--------------------+------------------------+-----------------------+-------------------------+
| Perf Week: -79.65% | Insider Trans: -33.46% | Debt/Eq: 2.08 | |
+--------------------+------------------------+-----------------------+-------------------------+

The next section covers any insider trading if any are accessible.

Inside Trans: IMPACT BIOMEDICAL INC. (IBO) by Chan Heng Fai Ambrose (Unknown Title) on 2025-03-31
- Common Stock: 300000 shares at $1.028 (I)
- Common stock: 400000 shares at $0.982 (I)
- Common Stock: 650000 shares at $1.447 (I)
- Common Stock: 1176918 shares at $1.08 (I)

Inside Trans: IMPACT BIOMEDICAL INC. (IBO) by DSS, INC. (Unknown Title) on 2025-03-21
- Common Stock: 166600 shares at $3.3004 (I)
- Common Stock: 166600 shares at $3.3004 (I)
- Common Stock: 166600 shares at $3.3004 (I)
- Common Stock: 48281 shares at $3.1292 (D)
- Common Stock: 9858 shares at $3.15 (D)
- Common Stock: 47681 shares at $2.5011 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -24770000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.464
Average Volume: 11032879.77
30-Day High: 4.96
30-Day Low: 0.464

[Detailed Financials: TTM 2024]
- Total Assets: $20,290,000.0
- Total Liabilities: $13,053,000.0
- Total Equity: $7,237,000.0
- Current Assets: $2,448,000.0
- Current Liabilities: $9,785,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.3

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $1,998,000.0

[Detailed Financials: FY 2024]
- Total Assets: $20,290,000.0
- Total Liabilities: $13,053,000.0
- Total Equity: $7,237,000.0
- Current Assets: $2,448,000.0
- Current Liabilities: $9,785,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.3

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $1,998,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

IBO_OUT_19 [2025-04-04 04:03:23 -0400] 687 Bytes | 169 tokens | Cum: 5370 tkns (67.12% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

IBO_IN_21 [2025-04-04 04:03:23 -0400] 126 Bytes | 29 tokens | Cum: 5429 tkns (67.86% of 8k)
==========================================================================

====================================
[2025-04-04 04:03:23] # Analysis Completed
Elapsed Time: 32.95 seconds